Successful migraine prophylaxis with naproxen sodium.Neurology. 1985 Sep; 35(9):1304-10.Neur
Abstract
Naproxen sodium, a potent inhibitor of prostaglandin biosynthesis and platelet aggregation, was studied for efficacy in migraine prophylaxis in a randomized, double-blind, placebo-controlled, crossover trial. On naproxen treatment, 52% of the patients had no severe headaches, whereas 19% had no severe headaches during placebo. Naproxen sodium was much better than placebo when patients' diaries were reviewed for severity of attacks, nausea, vomiting, activity reduction, duration of headache, and decreased use of therapeutic medication. The degree of platelet inhibition did not correlate with efficacy in preventing headache. Naproxen sodium can be recommended as a drug of first choice for migraine prevention.
Pub Type(s)
Clinical Trial
Journal Article
Randomized Controlled Trial
Language
eng
PubMed ID
4022376
Citation
Welch, K M., et al. "Successful Migraine Prophylaxis With Naproxen Sodium." Neurology, vol. 35, no. 9, 1985, pp. 1304-10.
Welch KM, Ellis DJ, Keenan PA. Successful migraine prophylaxis with naproxen sodium. Neurology. 1985;35(9):1304-10.
Welch, K. M., Ellis, D. J., & Keenan, P. A. (1985). Successful migraine prophylaxis with naproxen sodium. Neurology, 35(9), 1304-10.
Welch KM, Ellis DJ, Keenan PA. Successful Migraine Prophylaxis With Naproxen Sodium. Neurology. 1985;35(9):1304-10. PubMed PMID: 4022376.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - Successful migraine prophylaxis with naproxen sodium.
AU - Welch,K M,
AU - Ellis,D J,
AU - Keenan,P A,
PY - 1985/9/1/pubmed
PY - 1985/9/1/medline
PY - 1985/9/1/entrez
SP - 1304
EP - 10
JF - Neurology
JO - Neurology
VL - 35
IS - 9
N2 - Naproxen sodium, a potent inhibitor of prostaglandin biosynthesis and platelet aggregation, was studied for efficacy in migraine prophylaxis in a randomized, double-blind, placebo-controlled, crossover trial. On naproxen treatment, 52% of the patients had no severe headaches, whereas 19% had no severe headaches during placebo. Naproxen sodium was much better than placebo when patients' diaries were reviewed for severity of attacks, nausea, vomiting, activity reduction, duration of headache, and decreased use of therapeutic medication. The degree of platelet inhibition did not correlate with efficacy in preventing headache. Naproxen sodium can be recommended as a drug of first choice for migraine prevention.
SN - 0028-3878
UR - https://www.unboundmedicine.com/medline/citation/4022376/full_citation
DB - PRIME
DP - Unbound Medicine
ER -
